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Abstract
Dengue is a systemic viral infection transmitted between humans by Aedes mosquitoes1. For some 
patients dengue is a life-threatening illness2. There are currently no licensed vaccines or specific 
therapeutics, and substantial vector control efforts have not stopped its rapid emergence and global 
spread3. The contemporary worldwide distribution of the risk of dengue virus infection4 and its 
public health burden are poorly known2,5. Here we undertake an exhaustive assembly of known 
records of dengue occurrence worldwide, and use a formal modelling framework to map the 
global distribution of dengue risk. We then pair the resulting risk map with detailed longitudinal 
information from dengue cohort studies and population surfaces to infer the public health burden 
of dengue in 2010. We predict dengue to be ubiquitous throughout the tropics, with local spatial 
variations in risk influenced strongly by rainfall, temperature and the degree of urbanisation. 
Using cartographic approaches, we estimate there to be 390 million (95 percent credible interval 
284-528) dengue infections per year, of which 96 million (67-136) manifest apparently (any level 
of clinical or sub-clinical severity). This infection total is more than three times the dengue burden 
estimate of the World Health Organization2. Stratification of our estimates by country allows 
comparison with national dengue reporting, after taking into account the probability of an apparent 
infection being formally reported. The most notable differences are discussed. These new risk 
maps and infection estimates provide novel insights into the global, regional and national public 
health burden imposed by dengue. We anticipate that they will provide a starting point for a wider 
discussion about the global impact of this disease and will help guide improvements in disease 
control strategies using vaccine, drug and vector control methods and in their economic 
evaluation. [285]
Dengue is an acute systemic viral disease that has established itself globally in both endemic 
and epidemic transmission cycles. Dengue virus infection in humans is often inapparent1,6 
but can lead to a wide range of clinical manifestations, from mild fever to potentially fatal 
dengue shock syndrome2. The lifelong immunity developed after infection with one of the 
four virus types is type-specific1 and progression to more serious disease is frequently, but 
not exclusively, associated with secondary infection by heterologous types2,5. No effective 
antiviral agents yet exist to treat dengue infection and treatment therefore remains 
supportive2. Furthermore, no licensed vaccine against dengue infection is available, and the 
most advanced dengue vaccine candidate did not meet expectations in a recent large trial7,8. 
Current efforts to curb dengue transmission focus on the vector, using combinations of 
chemical and biological targeting of Aedes mosquitoes and management of breeding sites2. 
These control efforts have failed to stem the increasing incidence of dengue fever epidemics 
and expansion of the geographical range of endemic transmission9. While the historical 
expansion of this disease is well documented, the potentially large burden of ill-health 
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attributable to dengue across much of the tropical and sub-tropical world remains poorly 
enumerated.
Knowledge of the geographical distribution and burden of dengue is essential for 
understanding its contribution to global morbidity and mortality burdens, in determining 
how to allocate optimally the limited resources available for dengue control and in 
evaluating the impact of such activities internationally. Additionally, estimates of both 
apparent and inapparent infection distributions form a key requirement for assessing clinical 
surveillance and for scoping reliably future vaccine demand and delivery strategies. 
Previous maps of dengue risk have used various approaches combining historical occurrence 
records and expert opinion to demarcate areas at endemic risk10-12. More sophisticated risk 
mapping techniques have also been implemented13,14, but the empirical evidence-base has 
since been improved, alongside advances in disease modelling approaches. Furthermore, no 
studies have used a continuous global risk map as the foundation for dengue burden 
estimation.
The first global estimates of total dengue virus infections were based on an assumed 
constant annual infection rate amongst a crude approximation of the population at risk (10% 
in 1 billion5 or 4% in 2 billion15), yielding figures of 80-100 million infections per year 
worldwide in 19885,15. As more information was collated on the ratio of dengue 
haemorrhagic fever to dengue fever cases and the ratio of deaths to dengue haemorrhagic 
fever cases, the global figure was revised to 50-100 million infections16,17, although larger 
estimates of 100-200 million have also been made10 (Figure 1). These estimates were 
intended solely as approximations but, in the absence of better evidence, the resulting figure 
of 50-100 million infections per year is widely cited and currently used by the World Health 
Organization (WHO). As the methods employed were informal, these estimates were 
presented without confidence intervals, and no attempt was made to assess geographical or 
temporal variation in incidence or the inapparent infection reservoir.
Here we present the outcome of a new project to derive an evidence-based map of dengue 
risk and estimates of apparent and inapparent infections worldwide based on the global 
population in 2010. We compiled a database of 8,309 geo-located records of dengue 
occurrence from a systematic search, resulting from 2,838 published literature sources as 
well as newer online resources18 (see Supplementary Information A; the full bibliography4 
and occurrence data are available from authors on request). Using these occurrence records 
we: chose a set of gridded environmental and socioeconomic covariates known, or 
hypothesised, to affect dengue transmission (see Supplementary Information B); 
incorporated recent work assessing the strength of evidence on national and sub-national-
level dengue present/absent status4 (Figure 2A); and built a boosted regression tree (BRT) 
statistical model of dengue risk that addressed the limitations of previous risk maps (see 
Supplementary Information C) to define the probability of occurrence of dengue infection 
(dengue risk) within each 5km × 5km pixel globally (Figure 2B). The model was run 336 
times to reflect parameter uncertainty and an ensemble mean map was created (see 
Supplementary Information C). We then combined this ensemble map with detailed 
longitudinal information on dengue infection incidence from cohort studies and built a non-
parametric Bayesian hierarchical model to describe the relationship between dengue risk and 
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incidence (see Supplementary Information D). Finally, we used the estimated relationship to 
predict the number of apparent and inapparent dengue infections in 2010 (see 
Supplementary Information E). Our definition of an apparent infection is consistent with that 
used by the cohort studies: an infection with sufficient severity to modify a person’s regular 
schedule, such as attending school. This definition encompasses any level of severity of the 
disease, including both clinical and sub-clinical manifestations.
We predict that dengue transmission is ubiquitous throughout the tropics with the highest 
risk zones in the Americas and Asia (Figure 2B). Validation statistics indicated high 
predictive performance of the BRT ensemble mean map with area under the receiver 
operating characteristic (AUC) of 0.81 (±0.02 SD, n = 336) (see Supplementary Information 
C). Predicted risk in Africa, though more unevenly distributed than in other tropical endemic 
regions, is much more widespread than suggested previously. Africa has the poorest record 
of occurrence data and, as such, increased information from this continent would help to 
better define the spatial distribution of dengue within it and to improve derivative burden 
estimates. We found high levels of precipitation and temperature suitability for dengue 
transmission to be most strongly associated among the variables considered with elevated 
dengue risk, although low precipitation was not found to strongly limit transmission (see 
Supplementary Information C). Proximity to low-income urban and peri-urban centres was 
also linked to greater risk, particularly in highly connected areas, suggesting that human 
movement between population centres is an important facilitator of dengue spread. These 
associations have previously been cited9, but have not been demonstrated at the global scale 
and highlight the importance of including socioeconomic covariates when assessing dengue 
risk.
We estimate that there were 96 million apparent dengue infections globally in 2010 (Table 
1). Asia bore 70% (67 [47-94] million infections) of this burden, and is characterised by 
large swathes of densely populated regions coinciding with very high suitability for disease 
transmission. India19,20 alone contributed 34% (33 [24-44] million infections) of the global 
total. The disproportionate infection burden borne by Asian countries is emphasized in the 
cartogram shown in Figure 2C. The Americas contributed 14% (13 [9-18] million 
infections) of apparent infections worldwide, of which over half occurred in Brazil and 
Mexico. Our results indicate that Africa’s dengue burden is nearly equivalent to that of the 
Americas (16 (11–22) million infections, 16% of the global total), representing a 
significantly larger burden than previously estimated. This disparity supports the notion of a 
largely hidden African dengue burden, being masked by symptomatically similar illnesses, 
under-reporting and highly variable treatment-seeking behaviour6,9,20. The countries of 
Oceania contributed less than 0.2% of global apparent infections.
We estimate that an additional 294 (217–392) million inapparent infections occurred 
worldwide in 2010. These mild ambulatory or asymptomatic infections are not detected by 
the public health surveillance system and have no immediate implications for clinical 
management. However, the presence of this huge potential reservoir of infection has 
profound implications for: (i) correctly enumerating economic impact (for example, how 
many vaccinations are needed to avert an apparent infection) and triangulating with 
independent assessments of disability adjusted life years (DALYs)21; (ii) elucidating the 
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population dynamics of dengue viruses22; and (iii) hypothesising about population effects of 
future vaccine programmes23 (volume, targeting efficacy, impacts in combination with 
vector control), which will need to be administered to maximise cross-protection and 
minimize post-vaccination susceptibility.
The absolute uncertainties in the national burden estimates are inevitably a function of 
population size, with the greatest uncertainties in India, Indonesia, Brazil and China (see full 
rankings in Supplementary E table T4). In addition, comparing the ratio of the mean to the 
width of the confidence interval24 revealed the greatest contributors to relative uncertainty 
(see full rankings in Supplementary E table T4). These were countries with sparse 
occurrence points and low evidence consensus on dengue presence, such as Afghanistan or 
Rwanda (see Figure 2A), or those with ubiquitous high risk, such as Singapore or Djibouti, 
for which our burden prediction confidence interval is at its widest (see Figure SD2 in 
Supplementary D). Therefore, increasing evidence consensus and occurrence data 
availability in low consensus countries and assembling new cohort studies, particularly in 
areas of high transmission, will reduce uncertainty in future burden estimates. Our approach, 
uniquely, provides new evidence to help maximize the value and cost-effectiveness of 
surveillance efforts, by indicating where limited resources can be targeted to have their 
maximum possible impact in improving our knowledge of the global burden and distribution 
of dengue.
Our estimates of total infection burden (apparent and inapparent) are more than three times 
higher than the WHO predicted figure (Supplementary Information E). Our definition of an 
apparent infection is broad, encompassing any disruption to the daily routine of the infected 
individual, and consequently is an inclusive measurement of the total population affected 
adversely by the disease. Within this broad class, the severity of symptoms will affect 
treatment-seeking behaviours and the probability of a correct diagnosis in response to a 
given infection. Our definition is therefore more comprehensive than those of traditional 
surveillance systems, which, even in the most efficient system, report a much narrower 
range of dengue infections. By reviewing our database of longitudinal cohort studies, in 
which total infections in the community were documented exhaustively, we find that the 
biggest source of disparity between actual and reported infection numbers is the low 
proportion of individuals with apparent infections seeking care from formal health facilities 
(see Figure SE5 and Supplementary Information E for full analysis). Additional biases are 
introduced by misdiagnosis and the systematic failure of health management information 
systems to capture and report presenting dengue cases. By extracting the average magnitude 
of each of these sequential disparities from published cohort and clinical studies, we can 
recreate a hypothetical reporting chain with idealised reporting and arrive at estimates that 
are broadly comparable to those countries reported to the WHO. This is most clear in more 
reliable reporting regions such as the Americas. Systemic underreporting and low 
hospitalisation rates have important implications, for example, in the evaluation of vaccine 
efficacy based on reduced hospitalised caseloads. Inferences about these biases may be 
made from the comparison of estimated versus reported infection burdens in 2010, 
highlighting areas where particularly poor reporting might be strengthened (see 
Supplementary Information E).
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We have strived to be exhaustive in the assembly of contemporary data on dengue 
occurrence and clinical incidence and have applied new modelling approaches to maximise 
the predictive power of these data. It remains the case, however, that the empirical evidence 
base for global dengue risk is more limited than that available, for example, for Plasmodium 
falciparum25 and P. vivax26 malaria. Records of disease occurrence carry less information 
than those of prevalence and, as databases of the latter become more widespread, future 
approaches should focus on assessing relationships between seroprevalence and clinical 
incidence as a means of assessing risk27. Additional cartographic refinements are also 
required to help differentiate endemic- from epidemic-prone areas, to determine the 
geographic diversity of dengue virus types and to predict the distributions of future risk 
under scenarios of socioeconomic and environmental change.
The global burden of dengue is formidable and represents a growing challenge to public 
health officials and policymakers. Success in tackling this growing global threat is, in part, 
contingent on strengthening the evidence base on which control planning decisions and their 
impact are evaluated. It is hoped that this evaluation of contemporary dengue risk 
distribution and burden will help to advance that goal. [1935].
Methods
Assembly of the occurrence database and its quality control
Occurrence data comprised of point or polygon locations of confirmed dengue infection 
presence derived from both peer-reviewed literature and HealthMap alerts18,31 (see 
Supplementary Information A). An occurrence was defined as one or more laboratory or 
clinically confirmed infection(s) of dengue occurring at a unique location (a 5km × 5km 
pixel) within one calendar year. All occurrence data underwent manual review and 
automatic quality control to ensure information fidelity and precise geo-positioning. In total, 
9,648 and 1,622 occurrence locations were obtained from literature searches and HealthMap 
respectively. After the quality control procedures, our final dataset contained 8,309 
occurrence locations (5,216 point locations and 3,093 small polygon centroids) spanning a 
period from 1960 to 2012. We assume any record of dengue occurrence, regardless of its 
age, represented an environment permissible for the disease, since dengue has expanded 
from a focal disease in Asia to a cosmopolitan disease of the tropics.
Explanatory covariates
We assembled gridded global data for a suite of eight explanatory covariates. The covariates 
were chosen based on factors known or hypothesised to contribute to suitability for dengue 
transmission (see Supplementary Information B). These covariates included: (i) annual 
maximum and minimum precipitation variables from a Fourier processed32 synoptic annual 
series interpolated from global meteorological stations33; (ii) a biological model combining 
the effects of temperature on the extrinsic incubation period of dengue virus and life-span of 
the Aedes aegypti vector to quantify the dengue-specific temperature suitability for 
transmission28,34,35; (iii) Fourier-processed annual average normalised difference vegetation 
index36 (iv); categorical demarcations of urban and peri-urban areas37; (v) an urban 
accessibility metric defining the travel time to nearest city of 50,000 people or more by land- 
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or water-based travel38; and (vi) an indicator of relative poverty derived from the finest 
geographic scale data available for economic productivity and adjusted for purchasing 
power parity39. No covariate grids were shown to be adversely affected by multicollinearity 
(see Supplementary Information B) and were standardised to ensure identical spatial 
resolution, extent and boundaries. For point records, covariate values corresponded to the 
pixel value containing the location of the point. For polygon occurrence records, covariate 
values were averaged across the whole polygon.
Predicting the probability of occurrence (risk) of dengue transmission
We used a boosted regression tree (BRT) approach to establish a multivariate empirical 
relationship between the probability of occurrence of a dengue virus infection and the 
environmental conditions sampled at each site from the covariate suite. The BRT method 
has been shown to fit complicated response functions efficiently, while guarding against 
overfitting, and is therefore widely used for vector and disease distribution mapping40,41. 
The BRT approach combines regression trees42 with gradient boosting43, whereby an initial 
regression tree is fitted and iteratively improved upon in a forward stagewise manner 
(boosting) by minimising the variation in the response not explained by the model at each 
iteration (see Supplementary Information C).
Like other niche mapping approaches, the BRT models require not only presence data but 
also absence data defining areas of disease absence and potentially unsuitable environmental 
conditions at unsampled locations. Since data on absence of disease are not-definitive, 
pseudo-absence data estimate areas of disease absence instead. No consensus approach has 
been developed to optimise the generation of pseudo-absence data and we therefore created 
an evidence-based probabilistic framework for generating pseudo-absences, incorporating 
the main biasing factors in pseudo-absence generation, namely: (i) geographical extent; (ii) 
number; (iii) contamination bias; and (iv) sampling bias. To represent areas of absence, na 
pseudo-absence points29,44,45 were randomly generated based on dengue presence or 
absence certainty measures at a national or subnational level4. Pseudo-absence locations 
were restricted to a maximum distance μ from any recorded presence site46,47. Additionally, 
to compensate for “contamination” of true but unobserved presences within the generated 
pseudo-absences48, np pseudo-presence points were generated using the same procedure 
used to generate the pseudo-absences. Variation in the parameter set π = {μ, μa, μp} resulted 
in independent samples of the possible states of the real distribution, with all parameter 
combinations representing a null distribution of possible states. Therefore, rather than using 
an individual parameter combination from π, we created an ensemble49 of 336 BRT models 
spanning reasonable ranges in π and evaluated the central tendency as the mean across all 
336 BRT models (see Supplementary Information C). The final ensemble BRT model was 
used to predict a global map of the probability of occurrence of dengue virus infection at a 
5km × 5km resolution.
Estimation of dengue burden and populations at risk
Formal literature searches were conducted for serological dengue virus incidence surveys. 
Inclusion criteria were restricted to longitudinal surveys of seroconversion to dengue virus-
specific antibodies carried out in parallel with active symptom surveillance in a defined 
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cohort. The surveys were abstracted, standardised and geopositioned (see Supplementary 
Information D). In total, 54 dengue incidence surveys were collected. Of these, 39 contained 
information about the ratio of inapparent to apparent infections.
The empirical relationship between incidence and the probability of occurrence was 
represented using a Bayesian hierarchical model. We defined a negative binomial likelihood 
function50 with constant dispersion and a rate characterised by a highly flexible data-driven 
Gaussian process prior51. The Gaussian process prior was parameterised with a quadratic 
mean function and a squared exponential covariance function51. Uninformative hyperpriors 
were assigned hierarchically to the prior parameters and the full posterior distribution 
determined by Markov Chain Monte Carlo (MCMC) sampling52. The entire model was 
fitted separately for apparent and inapparent infection incidences, with missing inapparent to 
apparent ratio values imputed in the MCMC. Using human population gridded data for the 
year 201053, estimates of apparent and inapparent dengue infections were calculated 
nationally, regionally and globally. These estimates were then compared to national clinical 
cases reported to the WHO and differences between our cartographic estimates and the 
WHO surveillance estimates were reconciled in a comparative analysis addressing key 
factors in traditional surveillance underreporting (see Supplementary Information E). [973].
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Figure 1. Global estimates of total dengue infections
Comparison of previous estimates of total global dengue infections in individuals of all ages, 
1985 to 2010:  Halstead et al. 19885,  Monath et al. 199415,  Rodhain et al. 199617, 
Rigau-Perez et al. 199816,  TDR/WHO. scientific working group 200630,  Beatty et al. 
200910,  apparent infections from this study. Estimates are aligned to the year of estimate 
and, if not stated, aligned to the publication date. Red shading marks the credible interval of 
our current estimate, for comparison. Error bars from ref. 10 and ref. 16 replicated the 
confidence intervals provided in these publications.
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Figure 2. Global evidence consensus, risk and burden of dengue in 2010
a, shows National and subnational evidence consensus on complete absence (green) through 
to complete presence (red) of dengue4. b, shows the probability of dengue occurrence at 
5km × 5km spatial resolution of the mean predicted map (area under the receiver operator 
curve of 0.81 (±0.02 SD, n = 336)) from 336 boosted regression tree models. Areas with a 
high probability of dengue occurrence are shown in red and areas with a low probability in 
green. c, shows a cartogram of the annual number of infections for all ages as a proportion 
of national or sub-national (China) geographical area.
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Table 1
Estimated burden of dengue in 2010, by continent
Apparent Inapparent
Millions (credible interval) Millions (credible interval)
Africa 15.7 (10.5 - 22.5) 48.4 (34.3 - 65.2)
Asia 66.8 (47.0 – 94.4) 204.4 (151.8 – 273.0)
Americas 13.3 (9.5 - 18.5) 40.5 (30.5 - 53.3)
Oceania 0.18 (0.11 - 0.28) 0.55 (0.35 - 0.82)
Global 96 (67.1 - 135.6) 293.9 (217.0 – 392.3)
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